The invention provides a pharmaceutical composition comprising a compound of the formula (1): or a pharmaceutically acceptable salt or tautomer thereof; wherein R1 and R2 are each selected from hydrogen and methyl, provided that at least one of R1 and R2 is hydrogen; and X is CHOH or C=O; and a pharmaceutically acceptable carrier. Also provided are novel compounds wherein R1 and R2 are each selected from hydrogen and methyl, wherein at least one of R1 and R2 is hydrogen; and X is CHOH or C=O; provided that the hydrogen atoms in positions 3 and 11b are present in a cis relative orientation when (i) R1 and R2 are both hydrogen, or (ii) R1 is hydrogen and R2 is methyl.
Rapid and Simple Access to α-(Hetero)arylacetonitriles from <i>Gem</i>-Difluoroalkenes
A scalable cyanation of gem-difluoroalkenes to (hetero)arylacetonitrile derivatives was developed. This strategy features mild reaction conditions, excellent yields, wide substrate scope, and broad functional group tolerance. Significantly, in this reaction, aqueous ammonia offers a “N” source for the “CN” reagent and entirely avoids the use of toxic cyanating reagents or metal catalysis. Hence, we
This application describes substituted 1,3,4,6,7,11b-hexahydro-benzo(a)quinolizine compounds, pharmaceutical compositions containing them, processes for making them and their therapeutic methods.